• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

    5.000 +0.260 (+5.49%)
    Delayed Quote Updated: 2:38 PM EDT, Oct 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Aligos Therapeutics, Inc. - Common stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
    Topline data expected to be available late 3Q2027 
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
    Interim analyses on track for the first and second half of 2026 
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
    Seasoned leader with global commercialization and marketing expertise 
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at HEP-DART 2025
    Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists 
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
    Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodium 
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Present at Upcoming Investor Conferences
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
    From Aligos Therapeutics
    Via GlobeNewswire
    News headline image
    Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
    From Aligos Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.